Patents by Inventor David H. Calhoun
David H. Calhoun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11034946Abstract: A engineered alpha-galactosidase A polypeptide comprising SEQ ID NO: 1 having at least one non-glycosylation mutation; and at least one glycosylation compensatory mutation is claimed.Type: GrantFiled: October 5, 2018Date of Patent: June 15, 2021Assignee: Research Foundation of The City University of New YorkInventors: David H. Calhoun, Erin S. Stokes, M. Lane Gilchrist
-
Patent number: 10967067Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The ionvention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.Type: GrantFiled: November 27, 2018Date of Patent: April 6, 2021Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Lane Gilchrist
-
Patent number: 10851360Abstract: In one embodiment, the invention provides a method of purifying recombinant alpha-galactosidase A. The method includes obtaining a lysate from cells recombinantly expressing alpha-galactosidase A grown in a cell culture medium having non-precipitating phosphate; contacting said lysate with a first chromatography media that binds ?-D-mannopyranosyl or ?-D-glucopyranosyl; eluting alpha-galactosidase A from the first chromatography media to generate a first eluate having alpha-galactosidase A, wherein said eluting includes at least one elution pause between 4 and 16 hours; contacting the first eluate with a second chromatography media that binds galactose binding proteins; and eluting alpha-galactosidase A from said second chromatography media to generate a second eluate containing said recombinant alpha-galactosidase A.Type: GrantFiled: March 5, 2018Date of Patent: December 1, 2020Assignee: Research Foundation of the City University of New YorkInventors: David H. Calhoun, Abass Abdullahi
-
Publication number: 20190083639Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The ionvention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.Type: ApplicationFiled: November 27, 2018Publication date: March 21, 2019Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Lane Gilchrist
-
Publication number: 20180362947Abstract: In one embodiment, the invention provides a method of purifying recombinant alpha-galactosidase A. The method includes obtaining a lysate from cells recombinantly expressing alpha-galactosidase A grown in a cell culture medium having non-precipitating phosphate; contacting said lysate with a first chromatography media that binds ?-D-mannopyranosyl or ?-D-glucopyranosyl; eluting alpha-galactosidase A from the first chromatography media to generate a first eluate having alpha-galactosidase A, wherein said eluting includes at least one elution pause between 4 and 16 hours; contacting the first eluate with a second chromatography media that binds galactose binding proteins; and eluting alpha-galactosidase A from said second chromatography media to generate a second eluate containing said recombinant alpha-galactosidase A.Type: ApplicationFiled: March 5, 2018Publication date: December 20, 2018Inventors: David H. Calhoun, Abass Abdullahi
-
Patent number: 10138474Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.Type: GrantFiled: August 19, 2013Date of Patent: November 27, 2018Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Lane Gilchrist
-
Patent number: 9909113Abstract: In one embodiment, the invention provides a method of purifying recombinant alpha-galactosidase A. The method includes obtaining a lysate from cells recombinantly expressing alpha-galactosidase A grown in a cell culture medium having non-precipitating phosphate; contacting said lysate with a first chromatography media that binds ?-D-mannopyranosyl or ?-D-glucopyranosyl; eluting alpha-galactosidase A from the first chromatography media to generate a first eluate having alpha-galactosidase A, wherein said eluting includes at least one elution pause between 4 and 16 hours; contacting the first eluate with a second chromatography media that binds galactose binding proteins; and eluting alpha-galactosidase A from said second chromatography media to generate a second eluate containing said recombinant alpha-galactosidase A.Type: GrantFiled: June 5, 2015Date of Patent: March 6, 2018Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Abass Abdullahi
-
Publication number: 20160040146Abstract: In one embodiment, the invention provides a method of purifying recombinant alpha-galactosidase A. The method includes obtaining a lysate from cells recombinantly expressing alpha-galactosidase A grown in a cell culture medium having non-precipitating phosphate; contacting said lysate with a first chromatography media that binds ?-D-mannopyranosyl or ?-D-glucopyranosyl; eluting alpha-galactosidase A from the first chromatography media to generate a first eluate having alpha-galactosidase A, wherein said eluting includes at least one elution pause between 4 and 16 hours; contacting the first eluate with a second chromatography media that binds galactose binding proteins; and eluting alpha-galactosidase A from said second chromatography media to generate a second eluate containing said recombinant alpha-galactosidase A.Type: ApplicationFiled: June 5, 2015Publication date: February 11, 2016Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Abass Abdullahi
-
Publication number: 20140050666Abstract: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by a liposome, said liposome externally comprising a negatively charged scavenger receptor ligand. The invention further encompasses a method of treating a lysosomal storage disease with the compositions listed above. The invention further encompasses a method of treating a lysosomal storage disease with an acylated, acetylated, or aconitylated lysosomal enzyme.Type: ApplicationFiled: August 19, 2013Publication date: February 20, 2014Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: David H. Calhoun, Lane Gilchrist
-
Patent number: 5179023Abstract: Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.Type: GrantFiled: May 7, 1990Date of Patent: January 12, 1993Assignee: Research Corporation Technologies, Inc.Inventors: David H. Calhoun, George Coppola